Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of OPC-6535 in active ulcerative colitis
2005-003724-19Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing OPC-6535 with Placebo (2 arms). Primary endpoint: Clinical improvement at week 8 based on the ITT population. Started Sep 2005; status: completed.
02
Drugs
tetomilast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2005-003724-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003724-19.